Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2010 2
2012 5
2013 5
2014 4
2015 1
2022 0
Text availability
Article attribute
Article type
Publication date

PubMed for id: 1405645

19 results
Results by year
Filters applied: . Clear all
Page 1
AXL kinase as a novel target for cancer therapy.
Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. Wu X, et al. Oncotarget. 2014 Oct 30;5(20):9546-63. doi: 10.18632/oncotarget.2542. Oncotarget. 2014. PMID: 25337673 Free PMC article. Review.
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. Costa C, et al. Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493829 Free article. Clinical Trial.
Mechanisms of resistance to EGFR targeted therapies.
Hrustanovic G, Lee BJ, Bivona TG. Hrustanovic G, et al. Cancer Biol Ther. 2013 Apr;14(4):304-14. doi: 10.4161/cbt.23627. Epub 2013 Jan 28. Cancer Biol Ther. 2013. PMID: 23358468 Free PMC article. Review.
19 results